Evidence map›Paper›PMID 35770295›Full record

Trial reportTechnology in cancer research & treatment

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.

Yanrong Luo, Boning Cai, Bo Li, Fang Liu, Lei Du, Dawei Zhao, Wenjun Fan, Linlin Meng, Xinxin Zhang, Lin Ma

Open access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yanrong LuoMedical School of Chinese PLA, Beijing, China.
Boning CaiDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.ORCID 0000-0003-2358-4806
Bo LiDepartment of Cardiology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
Fang LiuDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Lei DuDepartment of Radiation Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China.
Dawei ZhaoDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Wenjun FanDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Linlin MengDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Xinxin ZhangDepartment of Otolaryngology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Lin MaDepartment of Radiation Oncology, 104607First Medical Center of Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Nasopharyngeal NeoplasmsRadiotherapy, Intensity-ModulatedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinDocetaxelFluorouracilHumansNasopharyngeal CarcinomaProspective StudiesCisplatinDocetaxelFluorouracilacute toxicitycisplatinconcurrent chemoradiotherapydocetaxellocoregionally advanced nasopharyngeal carcinoma

Identifiers

PMID35770295
PMCPMC9251964
OpenAlexW4283762801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.